An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
CC
Catalio Capital Management
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
- Rounds participated in
- 5
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $385M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionBigHat Biosciences
$75MSeries C
ParticipantBasecamp Research
Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.
$140MSeries C
ParticipantEvvy
Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.
$40MSeries B
LeadSuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
ParticipantRatio Therapeutics
Developing best-in-class radiopharmaceuticals for cancer treatment
$70MSeries C
Role not disclosed